US FDA, USP Collaborate To Promote Generic Development In Reversal Of Biosimilar Clash
Executive Summary
Talks remain in early stages, but both sides thinking 'outside the box' to come up with potential policy updates to generate more generic competition and bring down drug prices.
You may also be interested in...
How Drug Promotion Might Change Under Trump's Rx Pricing Plan
DTC disclosure requirements are shiny but probably not substantive; copay navigator might be weightier.
Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?
US FDA softens its tone on idea and encourages industry to voice its (predominantly negative) opinion publicly.
Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue
To remain shielded from political forces that could change incentives, pharmaceutical industry must adopt 'a certain set of values,' US FDA Commissioner says.